Explanipedia

Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial Open

Yoshitaka Arase, Tomomi Okubo, Taeang Arai, Masanori Abe, Tadashi Namisaki , et al. · 2025

Background: Osteoporosis is a common complication in patients with primary biliary cholangitis (PBC). This study aimed to compare the efficacy and safety of denosumab and zoledronic acid (ZOL) in treating osteoporosis in PBC patients. Meth…

Clinicopathological Significance of Wnt Pathway-Related Genes and Proteins in Sporadic Small Bowel Adenocarcinoma Open

Takayoshi Nishimoto, Atsushi Tatsuguchi, Takeshi Yamada, Sho Kuriyama, Aitoshi Hoshimoto , et al. · 2025

Background/Objectives: The Wnt signaling pathway is pivotal in the adenoma-carcinoma sequence; however, its role in small bowel adenocarcinoma (SBA) remains insufficiently characterized. We analyzed the clinicopathological significance of …

Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma Open

Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka , et al. · 2025

Background: Atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) are standard first-line therapies for unresectable hepatocellular carcinoma (HCC). However, predictive biomarkers to guide treatment selection …

G-Protein-Coupled Receptor Class C Group 6 Member A (GPRC6A) and Serine Protease Inhibitor, Kazal Type 1 (SPINK1) Genotypes Associated With Refractory Functional Dyspepsia: A Potential Link to Endosonographic Features Open

S. Higashida, Seiji Futagami, Ken Nakamura, Shuhei Agawa, Mayu Habiro , et al. · 2025

Significant differences (p < 0.001) were observed in the ratio of abnormal pancreatic enzyme levels between patients with R-FD and those with FD. GPRC6A genotype was significantly associated with EUS features, and further studies wi…

Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus Open

Taeang Arai, Masanori Atsukawa, Chikako Nagao, Zento Yamada, Takahiro Rokugo , et al. · 2025

Aim This study aimed to clarify the impact of tirzepatide as a treatment for Type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Methods This single‐arm, prospective, observati…

Risk Stratification for Malignant Potential of Intraductal Papillary Mucinous Neoplasms Using the Apolipoprotein-A2 Isoforms Blood Test Open

Yuta Hasegawa, Norio Itokawa, Ayumi Kashiro, Michika Kitamura, Kengo Nagashima , et al. · 2025

INTRODUCTION: High-risk stigmata (HRS) and worrisome features (WFs) are imaging findings that reflect malignant potential of intraductal papillary mucinous neoplasms (IPMNs). The aim of this study was to determine the potential utility of …

Association Between Laboratory Values and Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis: A Multicenter, Retrospective Study Open

Kaori Koyano, Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Takao Miwa , et al. · 2025

Background/Objective: Recently, there has been an increasing need to implement the diagnosis of the presence of covert hepatic encephalopathy (CHE) in patients with cirrhosis. The aim of this study was to identify novel factors associated …

Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy Open

Chihiro Miwa, Sadahisa Ogasawara, Takuya Yonemoto, Sae Yumita, Tomomi Okubo , et al. · 2025

Aim Combination immunotherapy is the standard of care for advanced hepatocellular carcinoma (HCC). However, some patients are unsuitable for such treatment. This study investigated the safety and effectiveness of durvalumab monotherapy in …

Effects of Biologics on Fibrosis-4 Index in Patients with Psoriasis Open

Takashi Morita, Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai , et al. · 2025

Downregulation of platelets seems to be a major contributing factor for the increase in FIB-4 index in patients treated with TNF inhibitors. Although the FIB-4 index is a simple marker to screen for liver fibrosis, changes in this index sh…

Evaluation of Treatment Outcomes Using <span>dNLR</span> and <span>GNRI</span> in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma Open

Atsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Takeshi Hatanaka , et al. · 2025

Aim This study aims to investigate the clinical utility of the derived neutrophil‐to‐lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable hepatocellular car…

Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics Open

Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa , et al. · 2024

For patients with refractory psoriasis, close cooperation between dermatologists and hepatologists is essential to prevent progression of liver fibrosis.

Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis Open

Jonghyun Kim, Takanori Ito, Taeang Arai, Masanori Atsukawa, Miwa Kawanaka , et al. · 2024

Background: The Fibrosis-4 (FIB-4) index is widely recommended as a first-tier method for screening advanced hepatic fibrosis; however, its diagnostic performance is known to be suboptimal in patients with Type 2 diabetes mellitus (T2DM). …

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study Open

Fanpu Ji, Sally Tran, Eiichi Ogawa, Chung‐Feng Huang, Takanori Suzuki , et al. · 2024

In this diverse multinational real-world cohort of patients with various GTs, the overall cure rate was 96.9%, despite large numbers of patients with cirrhosis, HCC, TE, and GT3/6. SVR12 for GT3/6 with cirrhosis and TE was lower but still …

Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response cases. Open

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka , et al. · 2024

Aim This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them with partial response (PR) a…

Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study) Open

Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa , et al. · 2024

Summary This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This was an open-label, nonrando…

Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy Open

Masanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, Tomomi Okubo, Norio Itokawa , et al. · 2024

Introduction: Macrovascular invasion (MVI) is a strong prognostic factor for advanced hepatocellular carcinoma (HCC). The current criteria for radiological assessment are unclear in evaluating the impact of MVI on systemic th…

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab Open

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose , et al. · 2024

Kinetics of the hepatitis B core‐related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide Open

Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Toru Ishikawa, Hidenori Toyoda , et al. · 2024

Aim An association between hepatitis B core‐related antigen (HBcrAg) kinetics and hepatocarcinogenesis during nucleoside (t)id analog (NA) treatment has recently been reported. HBcrAg kinetics and factors associated with HBcrAg response du…

Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study Open

Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo , et al. · 2024

Introduction: The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses of IMbrave-150 and metanalyses of clinical …

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study Open

Hiroki Ono, Masanori Atsukawa, Akihito Tsubota, Taeang Arai, Kenta Suzuki , et al. · 2024

Background and Aim This study aimed to clarify the efficacy and safety of 48‐week pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) complicated by dyslipidemia. Methods A total of 110 p…

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma Open

Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama , et al. · 2024

Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total…

Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease Open

Tomomi Okubo, Masanori Atsukawa, Akihito Tsubota, Hiroki Ono, Tadamichi Kawano , et al. · 2024

Sarcopenia frequently and progressively occurs in patients with chronic liver disease. This study aimed to clarify the relationship between vitamin D levels and muscle mass loss. A total of 166 patients with chronic liver disease were enro…

Ramucirumab for advanced hepatocellular carcinoma in the current real world: A Japanese single-arm study post-REACH-2 (The R-evolution Study) Open

Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa , et al. · 2024

Background This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. Methods This was an open-labe…

Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma Open

Makoto Chuma, Haruki Uojima, Hidenori Toyoda, Atsushi Hiraoka, Yoshitake Arase , et al. · 2024

Background The aim of this study was to identify clinically significant biomarkers of a response to atezolizumab plus bevacizumab (ATZ + BV) therapy, and to target strategies against unresectable hepatocellular carcinoma (u-HCC). Method We…

Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma Open

Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda , et al. · 2024

Table S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open